A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival (PFS)
37 months
No
MD
Study Director
Amgen
Belgium: Directorate-General for Medicinal Products
20070509
NCT00819780
February 2009
March 2015
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Boise, Idaho |
Research Site | Arlington Heights, Illinois |
Research Site | Bloomington, Indiana |
Research Site | Hays, Kansas |
Research Site | Ashland, Kentucky |
Research Site | Baltimore, Maryland |
Research Site | Beverly, Massachusetts |
Research Site | Battle Kreek, Michigan |
Research Site | Belleville, New Jersey |
Research Site | Albuquerque, New Mexico |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Bennington, Vermont |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |